Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

被引：0
作者：
Rong Shi
Tong Lu
Grace Ku
Hao Ding
Tomohisa Saito
Leonid Gibiansky
Priya Agarwal
Xiaobin Li
Jin Yan Jin
Sandhya Girish
Dale Miles
Chunze Li
Dan Lu
机构：
[1] Genentech Inc.,
[2] Chugai Pharmaceutical Co.,undefined
[3] Ltd.,undefined
[4] QuantPharm LLC,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Ethnic sensitivity assessment; NHL; Non-hodgkin lymphoma; PK; Polatuzumab vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：347 / 359
页数：12
相关论文
共 50 条
[21]   Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma [J].
Dang, Nam H. ;
Fayad, Luis ;
McLaughlin, Peter ;
Romaguara, Jorge E. ;
Hagemeister, Fredrick ;
Goy, Andre ;
Neelapu, Sattva ;
Samaniego, Felipe ;
Walker, Pamela L. ;
Wang, Michael ;
Rodriguez, Maria A. ;
Tong, Ann T. ;
Pro, Barbara .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) :502-505
[22]   Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience [J].
Darcin, Tahir ;
Yigenoglu, Tugce Nur ;
Sahin, Derya ;
Bakirtas, Mehmet ;
Basci, Semih ;
Merdin, Alparslan ;
Yildiz, Jale ;
Ulu, Bahar Uncu ;
Tetik, Aysegul ;
Iskender, Dicle ;
Cakar, Merih Kizil ;
Dal, Mehmet Sinan ;
Altuntas, Fevzi .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S249-S250
[23]   Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey [J].
Dal, Mehmet Sinan ;
Ulu, Bahar Uncu ;
Uzay, Ant ;
Akay, Olga Meltem ;
Besisik, Sevgi ;
Yenerel, Mustafa Nuri ;
Celik, Serhat ;
Kaynar, Leylagul ;
Yucel, Orhan Kemal ;
Deveci, Burak ;
Sonmez, Mehmet ;
Mehtap, Ozgur ;
Bekoz, Huseyin Saffet ;
Sunu, Cenk ;
Salim, Ozan ;
Ulas, Turgay ;
Karti, Sami ;
Altuntas, Fevzi ;
Ferhanoglu, Burhan ;
Tuglular, Tulin Firat .
ANNALS OF HEMATOLOGY, 2023, 102 (01) :133-140
[24]   A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma [J].
Terui, Yasuhito ;
Rai, Shinya ;
Izutsu, Koji ;
Yamaguchi, Motoko ;
Takizawa, Jun ;
Kuroda, Junya ;
Ishikawa, Takayuki ;
Kato, Koji ;
Suehiro, Youko ;
Fukuhara, Noriko ;
Ohmine, Ken ;
Goto, Hideki ;
Yamamoto, Kazuhito ;
Kanemura, Nobuhiro ;
Ueda, Yasunori ;
Ishizawa, Kenichi ;
Kumagai, Kyoya ;
Kawasaki, Atsuko ;
Saito, Tomohisa ;
Hashizume, Misato ;
Shibayama, Hirohiko .
CANCER SCIENCE, 2021, 112 (07) :2845-2854
[25]   Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) [J].
Budde, Elizabeth ;
Ghosh, Nilanjan ;
Chavez, Julio ;
Lossos, Izidore S. ;
Mehta, Amitkumar ;
Dorritie, Kathleen ;
Kamdar, Manali ;
Negricea, Raluca ;
Song Pham ;
Hristopoulos, Maria ;
Huw, Ling-Yuh ;
O'Hear, Carol ;
Oki, Yasuhiro ;
To, Iris ;
Diefenbach, Catherine .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S393-S394
[26]   Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience [J].
Segman, Yafit ;
Ribakovsky, Elena ;
Avigdor, Abraham ;
Goldhecht, Yair ;
Vainstein, Vladimir ;
Goldschmidt, Neta ;
Harlev, Shimrit ;
Horwitz, Netanel ;
Gutwein, Odit ;
Gurion, Ronit ;
Itchaki, Gilad ;
Abadi, Uri ;
Nemets, Anatoly ;
Sofer, Orit ;
Zektser, Miri ;
Tadmor, Tamar ;
Dally, Nagib ;
Filanovsky, Kalman ;
Leiba, Merav ;
Sarid, Nadav ;
Benyamini, Noam ;
Herishanu, Yair ;
Ram, Ron ;
Perry, Chava ;
Avivi, Irit .
LEUKEMIA & LYMPHOMA, 2021, 62 (01) :118-124
[27]   Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy [J].
Argnani, Lisa ;
Broccoli, Alessandro ;
Pellegrini, Cinzia ;
Fabbri, Alberto ;
Puccini, Benedetta ;
Bruna, Riccardo ;
Tisi, Maria Chiara ;
Masia, Francesco ;
Flenghi, Leonardo ;
Nizzoli, Maria Elena ;
Musso, Maurizio ;
Salerno, Marilena ;
Scalzulli, Potito Rosario ;
Dessi', Daniela ;
Ferrarini, Isacco ;
Pennese, Elsa ;
Lucchini, Elisa ;
Rossi, Francesca Gaia ;
Minoia, Carla ;
Gherlinzoni, Filippo ;
Musto, Pellegrino ;
Patti, Caterina ;
Stefoni, Vittorio ;
Zinzani, Pier Luigi .
HEMASPHERE, 2022, 6 (12) :E798
[28]   Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab [J].
Saburi, Masuho ;
Sakata, Masanori ;
Kodama, Yousuke ;
Uraisami, Keiichi ;
Takata, Hiroyuki ;
Miyazaki, Yasuhiko ;
Wada, Junpei ;
Urabe, Shogo ;
Ohtsuka, Eiichi .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (03) :201-204
[29]   Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis [J].
Wang, Jianhong ;
Duan, Xiaohui ;
Yang, Lijie ;
Liu, Xiangxiang ;
Hao, Caixia ;
Dong, Hongjuan ;
Gu, Hongtao ;
Tang, Hailong ;
Dong, Baoxia ;
Zhang, Tao ;
Gao, Guangxun ;
Liang, Rong .
CELL TRANSPLANTATION, 2020, 29
[30]   Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan [J].
Izutsu, Koji ;
Ando, Kiyoshi ;
Nishikori, Momoko ;
Shibayama, Hirohiko ;
Teshima, Takanori ;
Kuroda, Junya ;
Kato, Koji ;
Imaizumi, Yoshitaka ;
Nosaka, Kisato ;
Sakai, Rika ;
Hojo, Seiichiro ;
Nakanishi, Tadashi ;
Rai, Shinya .
CANCER SCIENCE, 2021, 112 (09) :3627-3635
12345